Genome editing firm's Q2 net loss widened to $27.5 million, and loss per share was $0.73.
Company ended Q2 with $120.7 million in cash and expects runway through Q4 2027.
Scientific posters and awards at ISTH Congress
The company said it continued to advance MGX-001 toward IND submission, with IND-enabling studies expected to complete by the end of Q3 2026.
Metagenomi highlighted two scientific posters on MGX-001 that received awards at the 2026 ISTH Congress, including one with extensive non-human primate data.
Selected financial details and analyst coverage
Metric
Actual
Q2 Loss Per Share
$0.73
Q2 Net Loss
$27.48 million
Q2 Income from Operations
-$28.77 million
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy", 1 "hold" and no or .
MGX•
